LLY

1,014.52

-3.15%↓

JNJ

243.43

-0.55%↓

ABBV

224.55

-3.14%↓

NVS

165.62

-1.16%↓

MRK

120.01

-3.14%↓

LLY

1,014.52

-3.15%↓

JNJ

243.43

-0.55%↓

ABBV

224.55

-3.14%↓

NVS

165.62

-1.16%↓

MRK

120.01

-3.14%↓

LLY

1,014.52

-3.15%↓

JNJ

243.43

-0.55%↓

ABBV

224.55

-3.14%↓

NVS

165.62

-1.16%↓

MRK

120.01

-3.14%↓

LLY

1,014.52

-3.15%↓

JNJ

243.43

-0.55%↓

ABBV

224.55

-3.14%↓

NVS

165.62

-1.16%↓

MRK

120.01

-3.14%↓

LLY

1,014.52

-3.15%↓

JNJ

243.43

-0.55%↓

ABBV

224.55

-3.14%↓

NVS

165.62

-1.16%↓

MRK

120.01

-3.14%↓

Kodu・Aktsiate loetelu・Mirati Therapeutics Inc

Mirati Therapeutics Inc

Suletud

SektorTervishoid

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

Max

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	-0.05% downside

Uudiste sentiment

By Acuity

40%

60%

136 / 351 Pingereas Healthcare

Mirati Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

25. veebr 2026, 23:25 UTC

Kuumad aktsiad

Stocks to Watch: C3.ai, Salesforce, Pure Storage, Zoom

25. veebr 2026, 23:15 UTC

Tulu

Salesforce Sees Stable Growth; CEO Dismisses Talk of AI-Fueled 'SaaS-Pocalypse' -- 2nd Update

25. veebr 2026, 23:54 UTC

Market Talk

Gold Steady Ahead of U.S.-Iran Talks -- Market Talk

25. veebr 2026, 23:47 UTC

Tulu

Ferrovial 4Q Net EUR197M >FER.MC

25. veebr 2026, 23:45 UTC

Tulu

Ferrovial 4Q Rev EUR2.72B >FER.MC

25. veebr 2026, 23:42 UTC

Tulu

Nvidia Beats Back Bubble Fears With Record $68 Billion Sales in Fourth Quarter -- 4th Update

25. veebr 2026, 23:38 UTC

Market Talk

Nikkei May Rise, Tracking Wall Street's Gains -- Market Talk

25. veebr 2026, 23:25 UTC

Tulu

Trip.com: Company's Business Operations Remain Normal >TCOM

25. veebr 2026, 23:25 UTC

Tulu

Trip.com Gives Update on Investigation by China's State Administration for Market Regulation >TCOM

25. veebr 2026, 23:25 UTC

Tulu

Trip.com: Cannot Predict Status or Results of Investigation, Will Provide Updates on Conclusion >TCOM

25. veebr 2026, 23:25 UTC

Tulu

Trip.com Increase in FY Profit Primarily Due to Gain From Investments >TCOM

25. veebr 2026, 23:25 UTC

Tulu

Trip.com Will Continue to Communicate With SAMR on Compliance With Regulatory Requirements >TCOM

25. veebr 2026, 23:25 UTC

Tulu

Trip.com: SAMR Investigation Related to China's Anti-monopoly Law >TCOM

25. veebr 2026, 23:25 UTC

Tulu

Trip.com: Investigation Ongoing, Company Is Cooperating With SAMR >TCOM

25. veebr 2026, 23:25 UTC

Tulu

Trip.com Co-founders Min Fan, Qi Ji Resign From Positions >TCOM

25. veebr 2026, 23:25 UTC

Tulu

Trip.com: Fan Resigned as Director and President; Ji Resigned as a Director >TCOM

25. veebr 2026, 23:25 UTC

Tulu

Trip.com FY Rev CNY62.4B, Up 17% >TCOM

25. veebr 2026, 23:25 UTC

Tulu

Trip.com FY Net CNY33.3B Vs. Net CNY17.1B >TCOM

25. veebr 2026, 23:25 UTC

Tulu

Trip.com FY EPS CNY47.67 >TCOM

25. veebr 2026, 23:06 UTC

Tulu

Correction to Nvidia Fourth Quarter Results Article -- WSJ

25. veebr 2026, 23:01 UTC

Tulu

Nvidia Beats Back Bubble Fears With Record $68 Billion Sales in Fourth Quarter -- 3rd Update

25. veebr 2026, 23:00 UTC

Market Talk

Tulu

Global Equities Roundup: Market Talk

25. veebr 2026, 23:00 UTC

Market Talk

Tulu

Nvidia: Chinese Competitors Pose Risk to U.S. Dominance in AI -- Market Talk

25. veebr 2026, 22:56 UTC

Market Talk

Tulu

Nvidia CEO Says Customers Can't Grow Revenue Without Compute -- Market Talk

25. veebr 2026, 22:43 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Paramount Streaming Revenue Rises, but TV Segment Faces Headwinds -- WSJ

25. veebr 2026, 22:40 UTC

Market Talk

Tulu

Nvidia Says Agentic AI Has Reached Inflection Point -- Market Talk

25. veebr 2026, 22:40 UTC

Tulu

Karoon Energy Says Search for New CFO Well Advanced

25. veebr 2026, 22:39 UTC

Tulu

Karoon Energy Says CFO Ray Church to Leave Company

25. veebr 2026, 22:39 UTC

Tulu

Karoon Energy Says On-Market Share Buyback Program Ongoing at Moderated Level

25. veebr 2026, 22:38 UTC

Tulu

Karoon Energy Says Guidance for 2026 Key Metrics Unchanged

Võrdlus sarnastega

Hinnamuutus

Mirati Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

-0.05% langus

12 kuu keskmine prognoos

Keskmine 58.67 USD -0.05%

Kõrge 59 USD

Madal 58 USD

Põhineb 5 Wall Streeti analüütiku instrumendi Mirati Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

5 ratings

Osta

Hoia

Müü

Põhineb 5 analüütiku instrumendi Mirati Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

136 / 351 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

EBITDA

Ärikasum

Ettevõttest Mirati Therapeutics Inc

Mirati Therapeutics, Inc. is a clinical-stage oncology company. It is focused on developing therapeutics to address the genetic and immunological promoters of cancer. Its clinical programs consist of product candidates, including Adagrasib (MRTX849), MRTX1133, and Sitravatinib. MRTX849 is an oral small-molecule therapy designed to shrink difficult-to-treat cancers harboring the KRAS G12C mutation. MRTX1133 is a small molecule-inhibitor of the KRASG12D mutation, designed to treat patients with unmet need. Sitravatinib is a spectrum-selective receptor tyrosine kinase (RTK) inhibitor that can stimulate the body’s immune response to fight cancer. MRTX849 is in Phase III and Phase I/II clinical trials and MRTX1133 is in preclinical development. Sitravatinib is in a Phase III clinical trial, and Phase I/II clinical trials. It also has additional preclinical discovery programs, which includes first-in-class and best-in-class product candidates designed to address mutations and tumors.